Published in J Clin Epidemiol on April 01, 2004
RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol (2009) 1.44
Novel agents in renal carcinoma: a reality check. Ther Adv Med Oncol (2012) 1.11
Treatment response classification of liver metastatic disease evaluated on imaging. Are RECIST unidimensional measurements accurate? Eur Radiol (2009) 0.94
Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol (2014) 0.91
Post-treatment imaging of liver tumours. Cancer Imaging (2007) 0.89
Prognostic value of different CT measurements in early therapy response evaluation in patients with metastatic colorectal cancer. Cancer Imaging (2012) 0.81
Dynamic contrast-enhanced CT to assess metabolic response in patients with advanced non-small cell lung cancer and stable disease after chemotherapy or chemoradiotherapy. Eur Radiol (2013) 0.80
The start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer. Korean J Intern Med (2013) 0.78
Method of tumor volume evaluation using magnetic resonance imaging for outcome prediction in cervical cancer treated with concurrent chemotherapy and radiotherapy. Radiat Oncol J (2012) 0.77
External beam radiotherapy synergizes ¹⁸⁸Re-liposome against human esophageal cancer xenograft and modulates ¹⁸⁸Re-liposome pharmacokinetics. Int J Nanomedicine (2015) 0.77
Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Onco Targets Ther (2013) 0.76
PET imaging for Treatment Response in Cancer. PET Clin (2008) 0.75
Expression of mutant p53 in oral squamous cell carcinoma is correlated with the effectiveness of intra-arterial chemotherapy. Oncol Lett (2015) 0.75
Preventive effect of rebamipide gargle on chemoradiotherpy-induced oral mucositis in patients with oral cancer: a pilot study. J Oral Maxillofac Res (2012) 0.75
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol (2004) 6.95
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol (2007) 6.65
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol (2014) 6.61
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol (2014) 6.10
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol (2004) 4.68
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res (2002) 4.42
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res (2007) 3.74
Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology (2009) 3.30
Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol (2009) 3.11
Sex differences in the structural connectome of the human brain. Proc Natl Acad Sci U S A (2013) 3.06
Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J Clin Oncol (2011) 3.05
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol (2009) 2.97
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol (2009) 2.89
Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol (2010) 2.86
Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer (2005) 2.78
The Lung Image Database Consortium (LIDC) and Image Database Resource Initiative (IDRI): a completed reference database of lung nodules on CT scans. Med Phys (2011) 2.48
Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res (2005) 2.44
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40
Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg (2003) 2.36
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol (2012) 2.36
Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol (2010) 2.27
Urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in Medicare population. Urology (2011) 2.26
Lung cancer: computerized quantification of tumor response--initial results. Radiology (2006) 2.23
Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology (2004) 2.13
Diagnosis, management, and outcomes of 115 patients with hepatic hemangioma. J Am Coll Surg (2003) 2.09
A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res (2010) 1.98
Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer (2008) 1.94
NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw (2009) 1.86
Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement. Clin Cancer Res (2003) 1.81
Renal cortical tumors: use of multiphasic contrast-enhanced MR imaging to differentiate benign and malignant histologic subtypes. Radiology (2012) 1.75
Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study. J Clin Oncol (2006) 1.71
Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci Transl Med (2011) 1.56
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood (2011) 1.55
Marker-controlled watershed for lymphoma segmentation in sequential CT images. Med Phys (2006) 1.52
Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol (2009) 1.50
Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities. Radiology (2011) 1.48
Pulmonary metastases: effect of CT section thickness on measurement--initial experience. Radiology (2005) 1.48
Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology (2005) 1.44
Safety and efficacy of preoperative portal vein embolization with polyvinyl alcohol in 58 patients with liver metastases. AJR Am J Roentgenol (2005) 1.42
18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology. J Nucl Med (2006) 1.40
Heterogeneous impact of motion on fundamental patterns of developmental changes in functional connectivity during youth. Neuroimage (2013) 1.39
Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. J Clin Oncol (2005) 1.35
Promise and pitfalls of quantitative imaging in oncology clinical trials. Magn Reson Imaging (2012) 1.34
Early invasive cervical cancer: CT and MR imaging in preoperative evaluation - ACRIN/GOG comparative study of diagnostic performance and interobserver variability. Radiology (2007) 1.32
Automated quantification of body fat distribution on volumetric computed tomography. J Comput Assist Tomogr (2006) 1.31
Feasibility of using limited-population-based arterial input function for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced MRI data. Magn Reson Med (2008) 1.30
Methods for categorizing a prognostic variable in a multivariable setting. Stat Med (2003) 1.30
Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans. J Thorac Oncol (2010) 1.28
When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst (2012) 1.28
Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Am J Clin Oncol (2011) 1.24
A simulation study to evaluate the impact of the number of lesions measured on response assessment. Eur J Cancer (2008) 1.24
Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma. Cancer Res (2003) 1.24
Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology (2003) 1.22
Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer. Transl Oncol (2012) 1.21
Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. Radiology (2013) 1.21
Imaging surrogates of tumor response to therapy: anatomic and functional biomarkers. J Nucl Med (2009) 1.21
Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression. Urology (2006) 1.18
Segmentation of lung lesions on CT scans using watershed, active contours, and Markov random field. Med Phys (2013) 1.18
Socio-demographic patterning of referral, uptake and attendance in Physical Activity Referral Schemes. J Public Health (Oxf) (2007) 1.17
CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother (2012) 1.17
Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals. Eur J Radiol (2013) 1.17
Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: initial results. Radiology (2008) 1.16
Automatic detection of small lung nodules on CT utilizing a local density maximum algorithm. J Appl Clin Med Phys (2003) 1.15
Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy. J Nucl Med (2008) 1.15
Liver segmentation for CT images using GVF snake. Med Phys (2005) 1.15
Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Eur Radiol (2011) 1.13
Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann Surg Oncol (2011) 1.10
Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome. Br J Haematol (2012) 1.09
Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess (Full Rep) (2011) 1.08
Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer (2010) 1.07
Functional maturation of the executive system during adolescence. J Neurosci (2013) 1.07
Shape-constraint region growing for delineation of hepatic metastases on contrast-enhanced computed tomograph scans. Invest Radiol (2006) 1.04
CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology (2011) 1.03
1,2,4-triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D(3) receptor antagonists. J Med Chem (2007) 1.02
Lymph node segmentation from CT images using fast marching method. Comput Med Imaging Graph (2004) 1.00
Assessing the effect of CT slice interval on unidimensional, bidimensional and volumetric measurements of solid tumours. Cancer Imaging (2012) 1.00
Childhood leukaemia and infectious exposure: a report from the United Kingdom Childhood Cancer Study (UKCCS). Eur J Cancer (2007) 0.99
Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol (2002) 0.99
Urologist practice styles in the initial evaluation of elderly men with benign prostatic hyperplasia. Urology (2011) 0.98
A theoretical approach to choosing the minimum number of multiple tumors required for assessing treatment response. J Clin Epidemiol (2005) 0.98
Test-retest reproducibility analysis of lung CT image features. J Digit Imaging (2014) 0.98
Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. Ann Surg Oncol (2014) 0.96
Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001). J Thorac Oncol (2009) 0.96
Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials. Cancer (2003) 0.95
Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer (2009) 0.94
Correlation between tumor measurement on Computed Tomography and resected specimen size in lung adenocarcinomas. Lung Cancer (2011) 0.93
Preoperative radiographic assessment of hepatic steatosis with histologic correlation. J Am Coll Surg (2007) 0.92
Shoulder impingement presenting as neck pain. J Bone Joint Surg Am (2003) 0.92
Infectious illness in children subsequently diagnosed with acute lymphoblastic leukemia: modeling the trends from birth to diagnosis. Am J Epidemiol (2012) 0.92
Update on colorectal cancer imaging. Radiol Clin North Am (2007) 0.91
Localization of cancer susceptibility genes by genome-wide single-nucleotide polymorphism linkage-disequilibrium mapping. Cancer Res (2004) 0.91
Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. AJR Am J Roentgenol (2006) 0.91
Automated matching and segmentation of lymphoma on serial CT examinations. Med Phys (2007) 0.91
Early invasive cervical cancer: MRI and CT predictors of lymphatic metastases in the ACRIN 6651/GOG 183 intergroup study. Gynecol Oncol (2008) 0.91
Local changes in bone marrow at MRI after treatment of extremity soft tissue sarcoma. Skeletal Radiol (2008) 0.91
Malignant lesion segmentation in contrast-enhanced breast MR images based on the marker-controlled watershed. Med Phys (2009) 0.90
An optimal two-stage phase II design utilizing complete and partial response information separately. Control Clin Trials (2002) 0.89